Cantor Fitzgerald Begins Coverage on Esperion Therapeutics (NASDAQ:ESPR)

Analysts at Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $8.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 270.37% from the company’s previous close.

Several other brokerages also recently weighed in on ESPR. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.30.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $2.16 on Tuesday. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94. The business has a fifty day moving average price of $2.41 and a 200-day moving average price of $2.22. The stock has a market capitalization of $425.60 million, a price-to-earnings ratio of -3.38 and a beta of 1.01.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ESPR. Boomfish Wealth Group LLC grew its position in Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 5,102 shares during the period. Summit Financial LLC boosted its stake in shares of Esperion Therapeutics by 26.4% in the second quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 6,823 shares during the last quarter. National Bank of Canada FI grew its holdings in Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the period. SG Americas Securities LLC raised its position in Esperion Therapeutics by 45.3% during the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 11,658 shares in the last quarter. Finally, BOKF NA purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $26,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.